The combination of EGFR-TKIs and a β-catenin inhibitor abrogates the Notch3-dependent activation of β-catenin, which strongly attenuates tumor onset, improving the OS and RFS of NSCLC xenograft mice (Arasada et al., 2018). Here, EGFR is linked to neoplasm.